Downsizing didn’t cut our energy bills – but a plan to switch supplier, upgrade old appliances, and install a heat pump made ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Veru Inc (VERU) reports positive Phase 2B study results for Novosarm ... 3:20 pm Paci After losing some value lately, a hammer chart pattern has been formed for Veru (VERU), indicating that ...

When considering a weight loss medication — or any medication — it’s normal to wonder when the effects will kick in.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in individuals aged 12 ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

In the results, dual GLP-1/GIP agonist Zepbound (tirzepatide) outperformed GLP-1 agonist Wegovy (semaglutide) on all weight-loss endpoints at 72 weeks among patients with obesity or who were ...